UroGen Pharma Ltd.
URGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $90 | $83 | $64 | $48 |
| % Growth | 9.3% | 28.5% | 34% | – |
| Cost of Goods Sold | $9 | $9 | $8 | $5 |
| Gross Profit | $82 | $73 | $57 | $43 |
| % Margin | 90.2% | 88.7% | 88.1% | 89.3% |
| R&D Expenses | $57 | $46 | $53 | $48 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $93 | $83 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $121 | $0 | $0 | $88 |
| Operating Expenses | $178 | $139 | $136 | $135 |
| Operating Income | -$97 | -$66 | -$79 | -$92 |
| % Margin | -107.1% | -79.2% | -122.8% | -192.1% |
| Other Income/Exp. Net | -$27 | -$33 | -$29 | -$17 |
| Pre-Tax Income | -$124 | -$98 | -$108 | -$109 |
| Tax Expense | $3 | $4 | $2 | $1 |
| Net Income | -$127 | -$102 | -$110 | -$111 |
| % Margin | -140.4% | -123.6% | -170.6% | -230.7% |
| EPS | -2.96 | -3.55 | -4.79 | -4.96 |
| % Growth | 16.6% | 25.9% | 3.4% | – |
| EPS Diluted | -2.96 | -3.55 | -4.79 | -4.96 |
| Weighted Avg Shares Out | 43 | 29 | 23 | 22 |
| Weighted Avg Shares Out Dil | 43 | 29 | 23 | 22 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $3 | $1 | $0 |
| Interest Expense | $13 | $15 | $8 | $0 |
| Depreciation & Amortization | $0 | $2 | $2 | $1 |
| EBITDA | -$95 | -$60 | -$76 | -$91 |
| % Margin | -105.5% | -73% | -118.4% | -190.4% |